Skip to main content
Premium Trial:

Request an Annual Quote

Transgenomic Wraps Up Its Reorganization; 60 Staffers Cut, R&D Shops Shut

NEW YORK, Feb. 25 (GenomeWeb News) - Transgenomic yesterday said it has wrapped up a previously announced restructuring that resulted in 60 job cuts and the closure of R&D facilities related to its nucleic acids segment.

 

As part of the reorganization, which also saw the closure of two European field offices, Transgenomic will record approximately $3.5 million in fourth-quarter 2004 costs.

 

As GenomeWeb News reported in November 2004, Transgenomic disclosed plans to shutter a facility in Boulder, Colo., and lay off 60 staffers as part of a broader effort to trim costs.

 

At the time, the Omaha, Neb.-based company said it sold its oligonucleotide-manufacturing facility and downsized as it continues to struggle to trim expenses and save cash. Transgenomic announced the belt-tightening as part of its third-quarter 2004 financial report, in which a mild up-tick in revenue amid widening losses and slightly more than $1 million in the bank painted a bleak near-term picture for the company.

 

Transgenomic had also said it would lay off around 60 employees worldwide, and close two US-based research and development facilities linked to the firm's synthetic nucleic acid business, and two European field offices.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.